Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT newswireMT newswire2026/08/26 13:18
09:18 AM EDT, 08/26/2026 (MT Newswires) -- Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.5%. Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket. Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell. Summit Therapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well